Class of drug
- Microsomal triglyceride transfer protein inhibitor.
- Lipid lowering agent through inhibition of microsomal triglyceride transfer protein (MTP).
- Peripheral effects thought to be mediated by MTP inhibition at the level of the enterocyte, which blocks the uptake of dietary lipids, dose dependent decreases in serum cholesterol and triglyceride and an increased presence of triglyceride containing droplets in enterocytes.
- Also slightly reduces appetite due to accumulation of triglycerides inside enterocytes.
- No central effects.
- As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight management program, which also includes appropriate dietary and lifestyle changes (eg increased exercise).
Effects of overdosage
- Overdose of 3- or 5- times the recommended dose rate of 0.63 mg mitratapide/kg bodyweight (1 ml per 8 kg body weight) may produce soft or liquid feces, vomiting, salivation, anorexia, severe weight loss, emaciated appearance, dehydration and pale mucous membranes.
Other reported reactions
- Vomiting, diarrhea or softened stools. In most cases, these effects are mild and transient.
- Lethargy or weakness.
- Decreases in serum albumin , globulin , total protein , calcium and alkaline phosphatase .
- Increases in ALT and AST .
- Occasional hyperkalemia .
- May cause eye irritation - if accidental eye contact occurs, flush immediately with copious amounts of water.
Antidote for overdose
- In case of accidental overdosage, symptomatic therapy should be administered.
- No specific antidote is available.